Veyonda and Radiotherapy Profiled at Key Oncology Meeting
Filed with ASX · · 4 pages · English
In the deck
Earlier from Noxopharm
- Appendix 4E and Audited Financial Statements FY19
- More Evidence that Veyonda Enhances RT in Prostate Cancer
- NOX Receives FY19 Federal Government R&D Tax Rebate
- Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
- Noxopharm August 2019 Corporate Presentation
Later from Noxopharm
- Further Review Shows Major Clinical Benefits from Veyonda
- Potential Fundamental Change in Treatment of Brain Cancer
- Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
- Dr Graham Kelly to Assume CEO Role
- Appendix 4C - Quarterly
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm